Considering the evidence that CAV1/2 enhancer mutations reduce CAV1/2 expression and that CAV1/2 expression is beneficial to ALS phenotypes, we hypothesised a reduced survival duration and earlier age of onset in ALS patients who have CAV1 or CAV2 enhancer mutations. The gene discussed is CAV1; the disease is amyotrophic lateral sclerosis.